id: NEW:statin_therapy_to_cardiovascular_disease_mortality
name: Statin Therapy â†’ Cardiovascular Disease Mortality
from_node:
  node_id: NEW:statin_therapy
  node_name: Statin Therapy
to_node:
  node_id: cardiovascular_disease_mortality
  node_name: Cardiovascular Disease Mortality
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Statins inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis
  and lowering circulating LDL cholesterol levels'
- 'Step 2: Reduced LDL cholesterol decreases atherosclerotic plaque formation and
  progression in coronary and peripheral arteries'
- 'Step 3: Statins exert pleiotropic effects including anti-inflammatory properties
  that reduce systemic inflammation and vascular inflammation'
- 'Step 4: Statins demonstrate antifibrotic properties that may reduce arterial stiffness
  and improve vascular function'
- 'Step 5: These combined lipid-modulating and anti-inflammatory effects reduce the
  risk of cardiovascular events including myocardial infarction and stroke, thereby
  lowering CVD mortality'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Shiqin Zhang et al. 2024. A Systematic Review of Statins for
    the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism
    of Action. Molecules.'
  supporting_citations: []
description: Statin therapy reduces cardiovascular disease mortality through multiple
  mechanisms. Statins are primarily known for their lipid-modulating effects, reducing
  LDL cholesterol through HMG-CoA reductase inhibition. Additionally, statins exhibit
  anti-inflammatory and antifibrotic properties that provide cardiovascular protection
  beyond lipid lowering. In populations with NAFLD/NASH, where CVD represents the
  leading cause of mortality, statin therapy may be particularly beneficial. The review
  also notes potential benefits through modulation of gut microbiota, reducing systemic
  inflammation.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: NASH/NAFLD comorbidity
  direction: strengthens
  strength: moderate
  description: In NASH patients, CVD is the most common cause of death compared to
    liver-related causes, making statin therapy particularly relevant for reducing
    mortality in this population
